Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma

Taus, Álvaro; Camacho, Laura; Rocha, Pedro; Hardy-Werbin, Max; Pijuán, Lara; Piquer, Gabriel; López, Eva; Dalmases, Alba; Longarón, Raquel; Clavé, Sergi; Salido, Marta; Albanell, Joan; Bellosillo, Beatríz; Arriola, Edurne

doi:10.1016/j.cllc.2018.03.015

Cited by 44 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several previous studies have suggested the usefulness of liquid biopsy for prediction of the efficacy of EGFR‐TKI treatment, the utility of this approach has remained unclear because plasma samples were collected retrospectively, at only a few time points, or from a small number of patients. In the present study, a total of 553 plasma samples was prospectively collected from 100 patients every 12 weeks during EGFR‐TKI treatment and were analyzed by ddPCR.…”

Section: Discussionmentioning

confidence: 99%

“…Although several previous studies have suggested the usefulness of liquid biopsy for prediction of the efficacy of EGFR-TKI treatment, [15][16][17][18][19] the utility of this approach has remained unclear because plasma samples were collected The median values for PFS (mPFS), the P value for the difference between the 2 curves as determined with a log-rank test, and the hazard ratio (HR) together with its 95% CI are indicated. Cancer January 1, 2020 retrospectively, at only a few time points, or from a small number of patients.…”

Section: Discussionmentioning

confidence: 99%

“…Although monitoring of EGFR ‐activating mutations in plasma has been suggested to be informative for prediction of the efficacy of EGFR‐TKIs, its usefulness has remained unclear. To clarify the potential of liquid biopsy for prediction of EGFR‐TKI efficacy, we have now undertaken a multicenter prospective biomarker study with NSCLC patients positive for EGFR ‐activating mutations.…”

Section: Introductionmentioning

confidence: 99%

“…Liquid biopsy thus offers a promising alternative to tissue biopsy and has been applied to Cancer January 1, 2020 clinical practice to detect activating mutations or the tyrosine kinase inhibitor (TKI) resistance-conferring T790M mutation of EGFR in patients with NSCLC. [11][12][13][14] Although monitoring of EGFR-activating mutations in plasma has been suggested to be informative for prediction of the efficacy of EGFR-TKIs, 11,[15][16][17][18][19] its usefulness has remained unclear. To clarify the potential of liquid biopsy for prediction of EGFR-TKI efficacy, we have now undertaken a multicenter prospective biomarker study with NSCLC patients positive for EGFR-activating mutations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Iwama

Sakai

Hidaka

et al. 2019

Cancer

View full text Add to dashboard Cite

Background The aim of this study was to evaluate the potential of liquid biopsy for prediction of the efficacy of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) treatment and for assessment of the changes in genetic alterations during such treatment. Methods Plasma samples were prospectively collected from non–small cell lung cancer patients with EGFR‐activating mutations during EGFR‐TKI treatment until disease progression and were analyzed for such mutations with droplet digital polymerase chain reaction and for other somatic alterations with next‐generation sequencing. Results One hundred patients, including 87 who were EGFR‐TKI naïve, were enrolled. Median progression‐free survival was significantly shorter for EGFR‐TKI–naïve patients with EGFR‐activating mutations detected in plasma at baseline than for those without them (7.9 vs 19.0 months; P < .001), with the values being significantly longer for initially positive patients who became negative for these mutations at 12 or 24 weeks than for those who remained positive. An increase in the number of alleles positive for EGFR‐activating mutations in plasma during treatment was associated with disease progression, with a hazard ratio of 4.72 (95% CI, 2.07‐10.79; P < .001) for EGFR‐TKI–naïve patients showing an increase within 36 weeks. For 55 patients with available samples, the total number of somatic alterations (other than activating mutations or T790M of EGFR) in plasma was higher at disease progression than at baseline (33 vs 19; P = 0.04). Conclusion Liquid biopsy shows potential for prediction of EGFR‐TKI efficacy and elucidation of clonal tumor evolution during targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Iwama

Sakai

Hidaka

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…It has many advantages, as it is a minimally invasive technique that can be used at diagnosis or during follow-up. [96,97]. Circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), circulating exosomes, platelet RNA, and circulating tumour RNA (ctRNA) are included in the definition of liquid biopsy.…”

Section: The Role Of Liquid Biopsy In Nsclcmentioning

confidence: 99%

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

et al. 2019

View full text Add to dashboard Cite

In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.

show abstract

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

Dziadziuszko

Hung²,

Wang³

et al. 2022

Molecular Oncology

View full text Add to dashboard Cite

Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non‐invasive in vitro next‐generation sequencing (NGS)‐based diagnostic, detects genomic alterations in plasma circulating tumour DNA (ctDNA). We evaluated the clinical validity of F1L CDx as an aid in identifying patients with NTRK‐fp or ROS1‐fp tumours and assessed the genomic landscape pre‐ and post‐entrectinib treatment. Among evaluable pre‐treatment clinical samples (N = 85), positive percentage agreements between F1L CDx and clinical trial assays (CTAs) were 47.4% (NTRK fusions) and 64.5% (ROS1 fusions); positive predictive value was 100% for both. The objective response rate for CTA+ F1L CDx+ patients was 72.2% in both cohorts. The median duration of response significantly differed between F1L CDx+ and F1L CDx− samples in ROS1‐fp (5.6 vs. 17.3 months) but not NTRK‐fp (9.2 vs. 12.9 months) patients. Fifteen acquired resistance mutations were detected. We conclude that F1L CDx is a clinically valid complement to tissue‐based testing to identify patients who may benefit from entrectinib and those with acquired resistance mutations associated with disease progression.

show abstract

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma

Cited by 44 publications

References 28 publications

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

Contact Info

Product

Resources

About